is vyvanse a glp-1 Agonist for Binge Eating Disorder: Evidence and Safety Ditching Wegovy for Vyvanse: Can

Metabolic Medical Centers will work with you to develop an individualized plan based on your goals and lifestyle needs

Gallbladder Disease and Pancreatitis Gallbladder problems, including gallstones, have been associated with significant weight loss and with GLP-1-based therapies more broadly

Contrave and Wegovy are two brand-name prescription drugs approved for weight management in adults with obesity or who are overweight with at least one weight-related condition, such as high blood pressure (hypertension) or Type 2 diabetes

doi: 10.1186/s12933-023-01765-z

Contrave combines naltrexone and bupropion, and neither is classified as a stimulant medication

A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users